News from NORD

FDA Launches Expanded Access Navigator


 

Patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy and who seek access to potentially life-saving investigational drugs can use the FDA’s new Expanded Access Navigator to guide them through the process. The Navigator was a team effort led by the Reagan-Udall Foundation in collaboration with patient advocacy groups, the pharmaceutical industry, the FDA, and others in the Federal government.

Recommended Reading

Registration Is Open for Spinal CSF Leak Foundation Symposium
MDedge Hematology and Oncology
Rare Neuro-Immune Disorders Symposium Is Planned
MDedge Hematology and Oncology
CDC Offers Free Webinar on Bleeding Disorders in Women and Girls
MDedge Hematology and Oncology
FDA approves Rebinyn for hemophilia B treatment
MDedge Hematology and Oncology
TRK inhibitor shows ‘striking’ activity, durability across diverse adult and pediatric cancers
MDedge Hematology and Oncology
Blood markers can detect early pancreatic cancer
MDedge Hematology and Oncology
Bone marrow transplantation for epidermolysis bullosa continues to evolve
MDedge Hematology and Oncology
Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products
MDedge Hematology and Oncology
FDA Commissioner to Present Keynote Address at NORD Summit
MDedge Hematology and Oncology
Examining the Role of Caregivers at NINR Caregiving Summit
MDedge Hematology and Oncology